0      0

2022 AABB Annual Meeting

AM22-MN23-L - AM22-MN23-L: Effects of Transfusion on Bone Marrow Health and Transplant Outcomes in Sickle Cell Disease (Live)

Oct 3, 2022 3:00pm ‐ Oct 3, 2022 4:00pm

Credits: None available.


Bone marrow pathology in SCD, such as decreased mesenchymal stem cell function and disordered vasculature, has recently been described in pre-clinical models and has been shown to be responsive to red cell transfusion. A speaker will review her and others’ research in this area and its implications for peri-transplant transfusion support. Another speaker will discuss the association of HLA and red cell alloantibodies with important allogeneic transplant outcomes in SCD such as graft versus host disease, donor T cell chimerism, and even overall survival. Both speakers will speak to the implication of these findings for best practice transfusion support for SCD patients pre- and peri-transplant.

Learning Objectives:
  • Describe the potential of transfusion to improve allogeneic transplant and gene therapy outcomes in SCD through its effects on the bone marrow microenvironment.
  • Describe the association of HLA and red cell alloantibodies with allogeneic transplant outcomes in SCD.
  • Discuss best practice of transfusion support for SCD patients pre- and peri-transplant in the autologous and allogeneic setting.



  • Patricia Shi, MD : Global Blood Therapeutics: Grant/Research Support (Secondary Investigators need not disclose)
  • Robert Nickel, MD : Nothing to Disclose


Credits: None available.

You must be logged in and own this session in order to post comments.